Mesalazine pharmacokinetics and NAT2 phenotype |
| |
Authors: | Hendrik Lück Martina Kinzig Alexander Jetter Uwe Fuhr Fritz Sörgel |
| |
Institution: | Department of Pharmacology, University Hospital, University of Cologne, Cologne, Germany. |
| |
Abstract: | Background Mesalazine undergoes extensive metabolism by N-acetylation. While there is some evidence for an involvement of N-acetyltransferase (NAT) type 1, a potential role of NAT type 2 (NAT2) in vivo has not been tested.
Methods In two studies in healthy young Caucasians, NAT2 phenotyping was carried out using a caffeine metabolic ratio in urine 4-6 h
postdose. In study A, 1,000 mg mesalazine doses were given thrice daily for 5 days, and urine and blood samples were drawn
during the last dosing interval. In study B, a 1,000 mg single dose was given, and samples were taken for 48 h postdose. Pharmacokinetics
of mesalazine and N-acetylmesalazine (LC-MS/MS) were calculated by noncompartmental methods.
Results NAT2 phenotype could be allocated unequivocally in 21 slow and 5 rapid acetylators in study A, and in 9 slow and 8 rapid acetylators
in study B. Geometric mean (CV%) values in study A for slow rapid] acetylators were as follows: mesalazine AUC 11.1 μg/mL·h
(51%) 12.0 μg/mL·h (52%)], N-acetylmesalazine AUC 27.7 μg/mL·h (32%) 30.5 μg/mL·h (27%)], mesalazine Ae 8.53% (89%) 9.03% (52%)], N-acetylmesalazine Ae 31.4% (46%) 32.2 (41%)]. Values in study B were as follows: mesalazine AUC 3.45 μg/mL·h (113%) 2.36 μg/mL·h
(87%)], N-acetylmesalazine AUC 21.3 μg/mL·h (29%) 18.0 μg/mL·h (39%)], mesalazine Ae 0.2% (256%) 0.1% (359%)], N-acetylmesalazine Ae 30.9% (44%) 18.1% (84%)]. Higher AUC and Ae values for mesalazine in steady state study indicate saturation
of mesalazine metabolism. Statistics provided no evidence for a true difference in mesalazine pharmacokinetics between slow
and rapid acetylators, and no significant correlation between NAT2 activity and any mesalazine pharmacokinetic parameter was
found.
Conclusion NAT2 has no major role in human metabolism of mesalazine in vivo. |
| |
Keywords: | Mesalazine NAT2 Genetic polymorphism Caffeine Phenotyping |
本文献已被 PubMed SpringerLink 等数据库收录! |
|